In the experimental autoimmune encephalomyelitis (EAE) model of MS, the BTK inhibitor evobrutinib diminished the antigen-dependent activation and maturation of B cells and decreased the release of pro-inflammatory cytokines [50]. The gene discussed is BTK; the disease is myeloid sarcoma.